logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness of HIV screening in acute care settings.

    Article - En anglais

    Background 

    Although screening inpatients for human immunodeficiency virus (HIV) in acute care hospital settings has been recommended, the cost-effectiveness of screening is not known.

    Objective 

    To estimate the cost-effectiveness of a voluntary screening program in acute care hospitals and associated clinics.

    Results 

    During the first year, an HIV screening program implemented in acute care hospital settings in which the seroprevalence of HIV infection is 1% or more would result in the identification of approximately 110 000 undetected cases of HIV infection.

    The program would result in expenditures of approximately $171 million for testing and counseling, and expenditures of approximately $2 billion for incremental medical care for the patients identified as having HIV infection during the first year of screening.

    When the seroprevalence of HIV is 1%, the cost-effectiveness of screening is $47 200 per year of life saved.

    When the effect of early identification of HIV infection on the patient's quality of life also is considered, screening is less cost-effective.

    Screening-induced reductions in risk behavior improve the cost-effectiveness of screening by preventing the transmission of HIV.

    Conclusion 

    The cost-effectiveness of screening for HIV in acute care settings in which the seroprevalence rate is 1% is within the range of other accepted interventions, exclusive of the effect of screening on quality of life.

    However, the cost-effectiveness of scr...

    Mots-clés Pascal : SIDA, Dépistage, Analyse coût efficacité, Programme sanitaire, Homme, Virose, Infection, Immunopathologie, Immunodéficit

    Mots-clés Pascal anglais : AIDS, Medical screening, Cost efficiency analysis, Sanitary program, Human, Viral disease, Infection, Immunopathology, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0161568

    Code Inist : 002B30A01A2. Création : 199608.